The total return over the past 12 months is +56.68% vs. +16.94% for the S&P 500. So far it's up +60.94% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +56.68% | +42.21% | +22.18% | +24.30% | +21.06% | +20.27% |
| Total Return CAGR | +56.68% | +42.21% | +22.18% | +24.30% | +21.06% | +20.27% |
| Revenue CAGR | +41.15% | +29.07% | +32.18% | +27.31% | +28.72% | +54.57% |
| Net Income CAGR | (25.78%) | +20.95% | +12.58% | N/A | N/A | N/A |
| EPS CAGR | (21.43%) | +21.27% | +22.68% | N/A | N/A | N/A |
| Free Cash Flow CAGR | +49.11% | +40.67% | +40.08% | N/A | N/A | N/A |
| Operating Cash Flow CAGR | +49.44% | +38.82% | +40.01% | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Halozyme Therapeutics, Inc. (HALO)
| Year | Start price | End price | HALO Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $67.30 | $108.31 | +60.94% | +14.51% | +46.43% |
| 2025 | $47.81 | $67.30 | +40.77% | +17.72% | +23.05% |
| 2024 | $36.96 | $47.81 | +29.36% | +24.89% | +4.47% |
| 2023 | $56.90 | $36.96 | (35.04%) | +26.19% | (61.23%) |
| 2022 | $40.21 | $56.90 | +41.51% | (18.17%) | +59.68% |
| 2021 | $42.71 | $40.21 | (5.85%) | +28.74% | (34.59%) |
| 2020 | $17.73 | $42.71 | +140.89% | +18.37% | +122.52% |
| 2019 | $14.63 | $17.73 | +21.19% | +31.22% | (10.03%) |
| 2018 | $20.26 | $14.63 | (27.79%) | (4.56%) | (23.23%) |
| 2017 | $9.88 | $20.26 | +105.06% | +21.70% | +83.36% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
